$45.23
1.33% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US69366J2006
Symbol
PTCT
Sector
Industry

PTC Therapeutics, Inc. Stock price

$45.23
+0.12 0.27% 1M
+10.57 30.50% 6M
+17.67 64.11% YTD
+15.86 54.00% 1Y
+4.18 10.18% 3Y
-3.58 7.33% 5Y
-8.39 15.65% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.61 1.33%
ISIN
US69366J2006
Symbol
PTCT
Sector
Industry

Key metrics

Market capitalization $3.49b
Enterprise Value $2.88b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.19
P/S ratio (TTM) P/S ratio 3.87
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 12.84%
Revenue (TTM) Revenue $900.66m
EBIT (operating result TTM) EBIT $-127.76m
Free Cash Flow (TTM) Free Cash Flow $-186.27m
Cash position $1.01b
EPS (TTM) EPS $-5.94
P/E forward negative
P/S forward 4.45
EV/Sales forward 3.67
Short interest 9.26%
Show more

Is PTC Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

PTC Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a PTC Therapeutics, Inc. forecast:

9x Buy
60%
3x Hold
20%
3x Sell
20%

Analyst Opinions

15 Analysts have issued a PTC Therapeutics, Inc. forecast:

Buy
60%
Hold
20%
Sell
20%

Financial data from PTC Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
901 901
13% 13%
100%
- Direct Costs 205 205
10% 10%
23%
696 696
22% 22%
77%
- Selling and Administrative Expenses 143 143
2% 2%
16%
- Research and Development Expense 531 531
28% 28%
59%
22 22
107% 107%
2%
- Depreciation and Amortization 150 150
26% 26%
17%
EBIT (Operating Income) EBIT -128 -128
75% 75%
-14%
Net Profit -453 -453
29% 29%
-50%

In millions USD.

Don't miss a Thing! We will send you all news about PTC Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

PTC Therapeutics, Inc. Stock News

Neutral
PRNewsWire
6 days ago
WARREN, N.J. , Dec. 23, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that CEO Matthew B.
Neutral
PRNewsWire
10 days ago
- If approved, vatiquinone would be the first and only authorized therapy for children with FA - - PTC's fourth approval application submitted to FDA in 2024 - WARREN, N.J. , Dec. 19, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the vatiquinone New Drug Application (NDA) for the treatment of children and adults living with Friedreich ataxia (FA) t...
Neutral
PRNewsWire
11 days ago
WARREN, N.J. , Dec. 17, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Dec. 13, 2024, the company approved non-statutory stock options to purchase an aggregate of 1,725 shares of its common stock and 5,060 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to eight new employees.
More PTC Therapeutics, Inc. News

Company Profile

PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically-differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.

Head office United States
CEO Matthew Klein
Employees 995
Founded 1998
Website www.ptcbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today